INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Innovaderm’s CMO Will be Chairing the Clinical Outsourcing Group: CRO Summit!

Indero

Indero

Team of Experts

Author picture

Innovaderm is thrilled to announce that it’s Chief Medical Officer, Dr. Jasmina Jankicevic, will be chairing Pharmaceutical Business Conference Group‘s (PBC Group) Clinical Outsourcing Group: CRO Summit on December 3rd & 4th, 2024.

The Future of Clinical Research: Summit Chair Jasmina Jankicevic Weighs in on CRO Evolution – Read the interview now to learn on the changing environment for clinical research, and adapting role of CROs.

Proud member of the PBC Group advisory board, Dr. Jankicevic will be leading several discussions and sessions during the annual event:

  • Harnessing CRO’s Therapeutic Expertise to Accelerate Trial Delivery

CROs possess invaluable internal therapeutic area expertise that can significantly accelerate trial delivery when effectively utilized. Exploring how sponsors can leverage their CRO’s therapeutic lead to identify key opinion leaders, select the most suitable clinical trial sites, and determine the optimal geography for trial launch.
In this session, Jasmina will discuss strategies for maximizing the impact of therapeutic expertise, enhancing decision-making processes, and ultimately accelerating the delivery of clinical trials. Bridging the gap between CRO knowledge and execution to achieve optimal results.

  • Navigating the Future: Strategic Outlook for the CRO Industry

The biopharma landscape is experiencing unprecedented changes, driven by technological advancements, evolving funding models, and shifting healthcare dynamics. CROs are challenged to adapt their strategies to these transformative forces while continuing to deliver innovative therapies and value to patients.

In this session, the panel of CRO executives will examine the impact of AI, discuss emerging funding and payment models, consider the expanding role of pharmacies in trial delivery, and analyze industry-wide consolidation trends. The panel will also explore how these impactful changes are reshaping the landscape for trial delivery.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >